Very interesting --> Progeny of a single CAR-T cell induced complete remission in CLLhttps://t.co/Y6fPdNAn7r
— Andy Biotech (@AndyBiotech) May 31, 2018
Disruption of TET2 gene improves CD19 CAR-T efficacyhttps://t.co/g5fRYNZswH$NVS $GILD $CELG pic.twitter.com/vcNzc3lQTr
With these Nature Medicine papers describing new methods to treat CRS & neurotoxicity from CAR-T cells, avoiding expensive hospital stays/complications, important to remember science progress continues: costs today are solved tomorrow. https://t.co/sCtxTyntzc
— Robert Kruse, MD, PhD (@RobertLKruse) May 30, 2018
Good description of teamwork needed to make health data actionable. Subscribing to Your Patients — Reimagining the Future of Electronic Health Records | NEJM https://www-nejm- https://t.co/fcUQMmGRTA@dukeforge
— Robert M Califf (@califf001) May 23, 2018
Screening for #drugs that act via #allosteric interactions. Combo of #NMR fragment screening, #XRayCrystallography & #MAS NMR to screen for drugs that bind neonatal Fc receptor (#FcRn) and disrupt interaction with #IgG #PLOSBiology https://t.co/mLtdpTqJEV pic.twitter.com/j7ZwULpxR5
— PLOS Biology (@PLOSBiology) May 22, 2018
This is a really interesting article - boosting so-called disease associated microglia (neuronal damage sensors and responders) might be a preventative for neurodegenerative diseases https://t.co/Qu42qKEnDu
— Peter (@Biomaven) May 22, 2018
Nice review on #IPF in NEJMhttps://t.co/xTOMyBO2m6$FGEN $GLPG $BIIB $BMY $PFSCF $CELG pic.twitter.com/U2kTvzHvTO
— Andy Biotech (@AndyBiotech) May 10, 2018
Here is a useful summary of new approaches to the pricing of drugs, in @JAMA_current.
— Jeremy O'Connor (@oconnor_jeremy) April 30, 2018
A key step is for all to agree on the language in order to talk in a precise way about their risks vs benefits.
“Defining and Redefining Value-Based Drug Pricing” https://t.co/PRDJUNk2GA
Opening the black box of early pregnancy: Blastocyst-like structures generated solely from stem cells https://t.co/Bdn6Mexekl pic.twitter.com/5DtYaGzcC5
— flosz (@floszcrxl) May 2, 2018
Another humbling scientific failure to improve mild/moderate Alzheimer’s Disease.@Merck BACE1-inhibitor: reduced amyloid breakdown product by up to 80%, but no improved mental outcomes.https://t.co/DTgm1ChG7z pic.twitter.com/iDi4bKFuK9
— Amit V. Khera (@amitvkhera) May 2, 2018
Human knockouts and hets. Cool. https://t.co/BBQTnonVCy
— Jim Johnson, Ph.D. (@JimJohnsonSci) April 24, 2018
RSS Feed
